With respect to NFE2L2, 10% of patients with pancreatic carcinoma, 60% of patients with colorectal carcinoma and 50% glioblastoma biopsies have high expression levels (Figure 10B). This evidence concerns the gene NFE2L2 and exocrine pancreatic carcinoma.